Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

In Europe, regulators first rejected Eisai’s drug for similar reasons in July ... to better understand the brain bleeding risks. The company also has developed support programs to help doctors ...

After failing to pass muster with England’s drug reimbursement watchdog earlier this month, Eli Lilly’s Alzheimer’s disease ...

Manufacturers of Alzheimer’s disease drugs have identified blood tests as a way to accelerate diagnosis and treatment.

(Eli Lilly and Company via AP) Updated [hour]:[minute] [AMPM] [timezone ... That came a year after they approved a similar ...

Of note, Eisai previously experienced a great deal of success with a different Alzheimer's drug, called Aricept ... forecast of 56.5 billion yen. The company cited delays in the sales launch ...